Last Update 02 Mar 26

Fair value Decreased 7.04%

UNH: Medicare Advantage Reset And Rebate Actions Will Support Multi-Year Earnings Recovery

Our updated view trims UnitedHealth Group's fair value estimate to $364.63 from $392.24 as analysts factor in softer revenue growth assumptions, a slightly higher discount rate, and modestly lower long term profit expectations following a broad wave of reduced Street price targets on the stock.

Analyst Commentary

Street research on UnitedHealth has turned more cautious in the near term, with a cluster of lower price targets from multiple firms and a smaller group of more constructive views. For you as an investor, this mix of opinions translates into a debate around how quickly the company can adjust to policy and reimbursement shifts and what that means for valuation.

Bullish Takeaways

Bullish analysts who recently raised or initiated price targets in the US$400 to US$444 range see room for upside if the company executes on its turnaround plan and restores confidence in its long term earnings power.
Some research points to Medicare Advantage and other government managed care lines as areas where earnings could show earlier improvement, which, if realized, would support a higher multiple on those businesses.
Recent commentary on UnitedHealth's rebate plan describes it as a potentially strong move, suggesting that management is actively working to protect margins and competitive positioning.
Supportive research coverage argues that, over a multi year horizon, current sector conditions may eventually offer attractive entry points, with UnitedHealth positioned as a key beneficiary if execution stays on track.

Bearish Takeaways

Bearish analysts have cut price targets by US$20 to US$80, reflecting concerns that policy decisions such as the 2027 Medicare Advantage rate notice could weigh on revenue growth and profitability versus earlier expectations.
Several notes highlight the recent CMS related headlines as a meaningful headwind for managed care, which feeds directly into more conservative assumptions for UnitedHealth's long term margin profile.
Some commentary suggests that a quick recovery for health insurers after the CMS call is unlikely, leading to questions about how soon investors might gain clarity on earnings power and capital deployment.
A wave of reduced targets from large firms, including JPMorgan and others, points to a reassessment of risk around execution in the transition period, which is feeding into higher discount rates and more cautious valuation frameworks.

What's in the News

UnitedHealth is providing guidance for 2026, with management expecting more than US$439.0b in revenues, earnings from operations greater than US$24.0b, and earnings per share above US$17.10. This offers concrete reference points for longer term forecasts you may be building (company guidance).
A Senate committee report, covered by The Wall Street Journal, describes UnitedHealth as having used aggressive tactics to collect payment by boosting diagnoses for Medicare Advantage members. It also notes ongoing civil and criminal Justice Department probes into these practices, which may matter for your assessment of regulatory and legal risk (WSJ).
Hunterbrook Media alleges that CVS, UnitedHealth and Cigna used new subsidiaries to divert billions of dollars from health plans and patients. This highlights another thread of investigative scrutiny around business practices in the sector (Hunterbrook Media).
Sky News reports that private equity firm TPG is close to a deal worth more than £1b to acquire Optum's UK operation from UnitedHealth, a potential portfolio shift that could influence how you think about the mix of domestic and international earnings (Sky News).
The Wall Street Journal reports that former UnitedHealth CEO Stephen Hemsley has made private investments, through Cloverfields Capital, in healthcare startups without disclosure to UnitedHealth shareholders. You may want to factor this into your governance and stewardship assessment (WSJ).

Valuation Changes

Fair Value: trimmed from $392.24 to $364.63, a reduction of about 7%.
Discount Rate: moved slightly higher from 6.96% to 6.98%, reflecting a small increase in the rate used to discount future cash flows.
Revenue Growth: revised from 4.53% to 2.78%, a substantial cut to projected top line growth assumptions.
Net Profit Margin: adjusted marginally from 4.16% to 4.14%, indicating only a very small change in long term profitability assumptions.
Future P/E: edged down from 20.42x to 20.35x, signaling a slightly lower valuation multiple applied to expected earnings.

90 views

Key Takeaways

Strategic investments in technology and value-based programs aim to stabilize revenues and improve operational efficiency and margins.
Adjustments in Medicare strategies and focus on predictive care models may optimize future earnings and healthcare outcomes.
Challenges with Medicare, CMS risk model execution, and external funding pressures adversely impact UnitedHealth Group's financial performance and margins.

Catalysts

About UnitedHealth Group

Operates as a health care company in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The company is addressing unanticipated changes in Medicare membership profiles which impacted 2025 revenue. They are taking measures to ensure complex patients engage in clinical and value-based programs, which should help stabilize and potentially increase future revenue.
UnitedHealth Group is investing in new technology, including improving physician clinical workflows and enhancing digital engagement tools, which could improve operational efficiency and positively impact net margins.
Optum Rx's strong selling season with new wins and high customer retention suggests continued strong revenue performance, supported by efforts to counteract high drug prices and improve access to medicines.
UnitedHealth is planning to adjust Medicare Advantage plan designs and pricing based on observed trends, potentially optimizing future earnings and aligning better with prevailing care costs.
There is an emphasis on expanding value-based care and predictive engagements, such as the HouseCalls program, which may drive better health outcomes and reduce costs, thus improving net margins and overall earnings.

UnitedHealth Group Earnings and Revenue Growth

UnitedHealth Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming UnitedHealth Group's revenue will grow by 5.8% annually over the next 3 years.
Analysts assume that profit margins will shrink from 5.0% today to 4.0% in 3 years time.
Analysts expect earnings to reach $20.0 billion (and earnings per share of $22.36) by about August 2028, down from $21.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $30.7 billion in earnings, and the most bearish expecting $15.5 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 17.0x on those 2028 earnings, up from 11.6x today. This future PE is lower than the current PE for the US Healthcare industry at 21.0x.
Analysts expect the number of shares outstanding to decline by 1.92% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

UnitedHealth Group Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Unexpected increases in care activity and changes in member profiles, particularly in the Medicare businesses, have adversely impacted financial performance, leading to a reduction in projected earnings per share. This negatively influences net margins and earnings.
Insufficient execution in transitioning to the new CMS risk model has resulted in operational complexities and revenue challenges, particularly in the Medicare membership at Optum Health. This impacts revenue and net margins.
Premium increases, especially in the group Medicare Advantage business, have led to higher-than-expected care utilization, straining financial resources and potentially affecting net margins.
Market exits by health plans, driven by CMS risk model changes, have led to new members with lower-than-expected reimbursement levels, affecting Optum Health’s revenue and margins.
External pressures, such as ongoing funding cuts in recent years and concerns over potential future cuts to the Medicare Advantage program, are risks that could further strain net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $327.292 for UnitedHealth Group based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $626.0, and the most bearish reporting a price target of just $198.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $501.1 billion, earnings will come to $20.0 billion, and it would be trading on a PE ratio of 17.0x, assuming you use a discount rate of 6.8%.
Given the current share price of $271.81, the analyst price target of $327.29 is 17.0% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on UnitedHealth Group?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Views Mixed as UnitedHealth Group Price Target Rises Amid Improved Outlook and Ongoing Challenges